GSK-3 inhibitors

1 Provided are thiadiazolidine compounds of formula I wherein Ris an organic group having at least 8 atoms selected from C or O, which is not linked directly to the N through a -C(O)- and comprising at least an aromatic ring, and their pharmaceutical compositions. These compounds are selective GSK-3...

Full description

Saved in:
Bibliographic Details
Main Authors Medina Padilla, Miguel, Alonso Cascon, Mercedes, Dorronsoro Diaz, Isabel, Martinez Gil, Ana, Panizo Del Pliego, Gema, Fuertes Huerta, Ana, Perez Puerto, Maria Jose
Format Patent
LanguageEnglish
Published 17.04.2012
Online AccessGet full text

Cover

More Information
Summary:1 Provided are thiadiazolidine compounds of formula I wherein Ris an organic group having at least 8 atoms selected from C or O, which is not linked directly to the N through a -C(O)- and comprising at least an aromatic ring, and their pharmaceutical compositions. These compounds are selective GSK-3 inhibitors and have improved bioavailability. They are useful for the treatment of GSK-3 mediated diseases, among others Alzheimer's disease, type II diabetes, depression and brain injury.